Survodutide, a dual glucagon/GLP-1 receptor agonist, produced up to 8.7% weight loss in 16 weeks — significantly more than semaglutide's 5.3% — while matching semaglutide's blood sugar reduction in 413 type 2 diabetes patients.
8.7% weight loss in 16 weeksSurvodutide's highest dose group achieved nearly double the weight loss of semaglutide 1.0 mg (-5.3%) while matching its HbA1c reduction
What the researchers found
Survodutide produced dose-dependent HbA1c reductions up to -1.71% (DG3, 1.8 mg weekly) and weight loss up to -8.7% (DG6, 1.8 mg twice weekly) over 16 weeks. At lower doses, survodutide matched semaglutide for HbA1c reduction (-1.46% vs. -1.47%). At higher doses, survodutide produced significantly greater weight loss than semaglutide (-8.7% vs. -5.3%). Gastrointestinal adverse events were the most common side effects, occurring in 77.8% of survodutide-treated participants versus 52% with semaglutide and 52.5% with placebo. A clear dose-response relationship was observed for both efficacy and adverse events.
Why it matters
The addition of glucagon receptor agonism to GLP-1 signaling is a fundamentally different strategy from tirzepatide's GLP-1/GIP approach. Glucagon promotes energy expenditure and fat breakdown, which may explain survodutide's superior weight loss. This trial provides the first head-to-head data showing a dual glucagon/GLP-1 agonist outperforming semaglutide for weight loss in diabetic patients, supporting the glucagon agonism approach as a viable path to next-generation obesity treatment.
How the study worked
Phase II, multicentre, randomized, double-blind, parallel-group, placebo-controlled trial with an open-label semaglutide comparator arm. 413 participants aged 18-75 with type 2 diabetes (HbA1c 7.0-10.0%), BMI 25-50 kg/m², on background metformin. Six survodutide dose groups (0.3-2.7 mg weekly or 1.2-1.8 mg twice weekly), one semaglutide arm (up to 1.0 mg weekly), and one placebo arm. Primary endpoint: HbA1c change at 16 weeks. Key secondary endpoint: bodyweight change at 16 weeks.
What this study cannot tell us
This was a 16-week Phase II trial — too short to assess long-term efficacy, durability, or cardiovascular outcomes. The semaglutide arm was open-label (not blinded), introducing potential bias. The semaglutide dose was capped at 1.0 mg (not the 2.4 mg dose approved for obesity). GI adverse events were notably higher with survodutide, which could limit real-world adherence. The trial was funded by Boehringer Ingelheim, the manufacturer of survodutide.
How to read the evidence
This is a Phase II randomized controlled trial with 413 participants, published in Diabetologia. The randomized, blinded design for survodutide vs. placebo is strong, though the open-label semaglutide comparator is a limitation. Phase II trials establish dose-response but are not powered for definitive efficacy conclusions.
When this study was published
Published in 2024, this Phase II trial provides the dose-response foundation for survodutide's ongoing Phase III program, which will definitively test its efficacy and safety.
The bigger picture
The incretin drug race now has three distinct strategies: GLP-1 monoagonism (semaglutide), GLP-1/GIP dual agonism (tirzepatide), and GLP-1/glucagon dual agonism (survodutide). Each exploits different metabolic pathways. Survodutide's glucagon component may produce superior weight loss through increased energy expenditure and fat mobilization, complementing GLP-1's appetite suppression. If the GI side effects can be managed, survodutide could become a powerful competitor in the rapidly expanding metabolic drug market.
Questions still open
- Will survodutide's weight loss advantage over semaglutide persist or increase in longer Phase III trials?
- Can slower dose escalation protocols adequately mitigate the higher gastrointestinal side effect burden?
- How does survodutide's glucagon/GLP-1 approach compare to tirzepatide's GIP/GLP-1 approach in head-to-head trials?
Common questions
What makes survodutide different from semaglutide and tirzepatide?
If survodutide causes more side effects, is the extra weight loss worth it?
Read the original research
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia, 67(3), 470-482
Citation
Blüher, Matthias; Rosenstock, Julio; Hoefler, Josef; Manuel, Raymond; Hennige, Anita M. (2024). Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.. Diabetologia, 67(3), 470-482. https://doi.org/10.1007/s00125-023-06053-9